

Generics Global Group of Eight (G8) Industry Guide 2019-2028

Industry Report | 2024-12-20 | 303 pages | MarketLine

AVAILABLE LICENSES:

- Single user licence (PDF) \$1495.00
- Site License (PDF) \$2242.00
- Enterprisewide license (PDF) \$2990.00

Report description:

Generics Global Group of Eight (G8) Industry Guide 2019-2028

Summary

The G8 Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume , and forecast to 2028). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- The G8 countries contributed \$1,61,715.9 million in 2023 to the global generics industry, with a compound annual growth rate (CAGR) of 5.8% between 2019 and 2023. The G8 countries are expected to reach a value of \$2,15,698.2 million in 2028, with a CAGR of 5.9% over the 2023-28 period.

- Among the G8 nations, the US is the leading country in the generics industry, with market revenues of \$74,229.0 million in 2023. This was followed by Germany and the UK, with a value of \$27,662.3 and \$15,516.9 million, respectively.

- The US is expected to lead the generics industry in the G8 nations with a value of \$98,531.3 million in 2016, followed by Germany and the UK with expected values of \$33,345.6 and \$23,397.0 million, respectively.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the G8 generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the G8 generics market
- Leading company profiles reveal details of key generics market players' G8 operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the G8 generics market with five year forecasts by both value and volume

- Compares data from the US, Canada, Germany, France, UK, Italy, Russia and Japan, alongside individual chapters on each country

Reasons to Buy

- What was the size of the G8 generics market by value in 2023?
- What will be the size of the G8 generics market in 2028?
- What factors are affecting the strength of competition in the G8 generics market?
- How has the market performed over the last five years?
- How large is the G8 generics market in relation to its regional counterparts?

Table of Contents:

Table of Contents

1 Introduction

- 1.1. What is this report about?
- 1.2. Who is the target reader?
- 1.3. How to use this report
- 1.4. Definitions
- 2 Group of Eight (G8) Generics
- 2.1. Industry Outlook
- 3 Generics in Canada
- 3.1. Market Overview
- 3.2. Market Data
- 3.3. Market Segmentation
- 3.4. Market outlook
- 3.5. Five forces analysis
- 4 Macroeconomic Indicators
- 4.1. Country data
- 5 Generics in France
- 5.1. Market Overview
- 5.2. Market Data
- 5.3. Market Segmentation
- 5.4. Market outlook
- 5.5. Five forces analysis
- 6 Macroeconomic Indicators
- 6.1. Country data
- 7 Generics in Germany
- 7.1. Market Overview
- 7.2. Market Data
- 7.3. Market Segmentation
- 7.4. Market outlook
- 7.5. Five forces analysis
- 8 Macroeconomic Indicators
- 8.1. Country data
- 9 Generics in Italy
- 9.1. Market Overview
- 9.2. Market Data

9.3. Market Segmentation 9.4. Market outlook 9.5. Five forces analysis 10 Macroeconomic Indicators 10.1. Country data 11 Generics in Japan 11.1. Market Overview 11.2. Market Data 11.3. Market Segmentation 11.4. Market outlook 11.5. Five forces analysis 12 Macroeconomic Indicators 12.1. Country data 13 Generics in Russia 13.1. Market Overview 13.2. Market Data 13.3. Market Segmentation 13.4. Market outlook 13.5. Five forces analysis 14 Macroeconomic Indicators 14.1. Country data 15 Generics in The United Kingdom 15.1. Market Overview 15.2. Market Data 15.3. Market Segmentation 15.4. Market outlook 15.5. Five forces analysis 16 Macroeconomic Indicators 16.1. Country data 17 Generics in The United States 17.1. Market Overview 17.2. Market Data 17.3. Market Segmentation 17.4. Market outlook 17.5. Five forces analysis 18 Macroeconomic Indicators 18.1. Country data 19 Company Profiles 19.1. Teva Pharmaceutical Industries Ltd 19.2. Viatris Inc. 19.3. Sun Pharmaceutical Industries Ltd 19.4. Novartis AG 19.5. Sandoz Group AG 19.6. Hikma Pharmaceuticals Plc 19.7. Sanofi 19.8. Les Laboratoires Servier SAS 19.9. Stada Arzneimittel AG

19.10. Bayer AG 19.11. Lupin Ltd 19.12. Aspen Pharmacare Holdings Ltd 19.13. EMS SA 19.14. Eurofarma Laboratorios SA 19.15. Ache Laboratorios Farmaceuticos SA 19.16. Apotex Inc 19.17. Teva Canada Ltd 19.18. Sandoz Canada Inc 19.19. CSPC Pharmaceutical Group Ltd 19.20. Sino Biopharmaceutical Ltd 19.21. Hansoh Pharmaceutical Group Co Ltd 19.22. Dr. Reddy's Laboratories Ltd 19.23. Cipla Ltd 19.24. Aurobindo Pharma Ltd 19.25. PT Kalbe Farma Tbk 19.26. PT Indofarma Tbk 19.27. PT Sanbe Farma 19.28. PT Soho Global Health Tbk 19.29. Friulchem SpA 19.30. DOC Generici SRL 19.31. Recordati SpA 19.32. Daiichi Sankyo Co Ltd 19.33. Towa Pharmaceutical Co Ltd 19.34. Sawai Group Holdings Co Ltd 19.35. Toho Holdings Co Ltd 19.36. Laboratorios Silanes SA de CV 19.37. Pfizer Inc 19.38. Biocad 19.39. R-Pharm 19.40. Pharmstandard 19.41. AstraZeneca Plc 19.42. Bluefish Pharmaceuticals AB 19.43. Navamedic ASA 19.44. Novartis International AG 19.45. Beacons Pharmaceuticals Pte Ltd 19.46. Abbott Laboratories SA 19.47. Adcock Ingram Holdings Ltd 19.48. Dongkook Pharmaceutical Co Ltd 19.49. JW Holdings Corp 19.50. Hanmi Pharmaceuticals Co Ltd 19.51. Dong Wha Pharma Co Ltd 19.52. Esteve Pharmaceuticals SA 19.53. Abdi Ibrahim Ilac Sanayi ve Ticaret AS 19.54. Deva Holding AS 19.55. Sandoz Inc 20 Appendix

20.1. Methodology20.2. About MarketLine



Generics Global Group of Eight (G8) Industry Guide 2019-2028

Industry Report | 2024-12-20 | 303 pages | MarketLine

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License		Price
	Single user licence (PDF)		\$1495.00
	Site License (PDF)		\$2242.00
	Enterprisewide license (PDF)		\$2990.00
		VAT	
		Total	

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346. []** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	Phone*	
First Name*	Last Name*	
Job title*		
Company Name*	EU Vat / Tax ID / NIP number*	
Address*	City*	
Zip Code*	Country*	
	Date	2025-06-02
	Signature	

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com